Nanoform Finland Oyj Overview
Pro stress-test →Nanoform Finland is a nanoparticle medicine-enabling company providing advanced drug particle engineering services to pharma and biotech partners in Europe and North America. The company's proprietary Controlled Expansion of Supercritical Solutions (CESS) technology creates API nanoparticles as small as 10nm, enabling poorly soluble drugs to progress into clinical development by improving bioavailability and dissolution rates.
Strategic Profile
Pro stress-test →Nanoform's competitive advantage lies in its patented, scalable CESS technology and emerging Nanoform Biologics platform for high-dose subcutaneous delivery of large molecules. The company positions itself to reduce clinical trial attrition and extend product lifecycles while serving a high-value pharma market where formulation enhancement drives significant differentiation.
Competitive Landscape
Pro stress-test →Nanoform competes in the specialized pharmaceutical formulation services space against larger contract development and manufacturing organizations (CDMOs) and niche formulation specialists. Key competitive differentiation comes from proprietary CESS technology and growing biologics capabilities, though the market includes competitors offering alternative particle engineering and formulation solutions for similar pharma applications.
Industry Context
Nanoform Finland Oyj operates in Pharmaceutical Contract Development & Manufacturing (CDMO) / Nanotechnology Services.
Key facts
Founded: 2008 · Headquarters: Helsinki, Finland · Employees: 181 · Revenue: €3.66M · Market cap: €70M